The relation between glycemic control and HDL-C in type 2 diabetes: A preliminary step forward?

Diabetes Research and Clinical Practice

Volumn 104, Issue 1, 2014, Pages

  Barbarossa, G ^a   Renzi, A ^a   D'Erasmo, L ^a   Gallo, A ^a   Grieco, E ^a   Rossetti, M ^a   Carnovale, A ^a   Santilli, M ^a   Mandosi, E ^a   Coletta, P ^a   Pergolini, D ^a   Morano, S ^a   Maranghi, M ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Glycated haemoglobin; Glycemic control; HDL cholesterol; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COMPLIANCE; PATIENT MONITORING; PILOT STUDY; PROSPECTIVE STUDY; TREATMENT DURATION; ADOLESCENT; AGED; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIA; FOLLOW UP; METABOLISM; MIDDLE AGED; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROGNOSIS; YOUNG ADULT;

EID: 84898539110     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2013.12.061     Document Type: Article

References (9)

1. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435.
2. Barter P., Gotto A.M., LaRosa J.C., Maroni J., Szarek M., Grundy S.M., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357:1301-1310.
3. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79:8-15.
4. Brunzell J.D., Davidson M., Furberg C.D., Goldberg R.B., Howard B.V., Stein J.H., et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008, 31:811-822.
5. Schwartz G.G., Olsson A.G., Abt M., Ballantyne C.M., Barter P.J., Brumm J., et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012, 367:2089-2099.
6. AIM-HIGH Investigators, Boden W.E., Probstfield J.L., Anderson T., Chaitman B.R., Desvignes-Nickens P., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, 365:2255-2567.
7. Gatti A., Maranghi M., Bacci S., Carallo C., Gnasso A., Mandosi E., et al. Poor glycemic control is an independent risk factor for low HDL cholesterol in patients with type 2 diabetes. Diabetes Care 2009, 32:1550-1552.
8. Wägner A.M., Ordóñez-Llanos J., Caixàs A., Bonet R., de Leiva A., Pérez A. Quantitative effect of glycaemic improvement on the components of diabetic dyslipidaemia: a Longitudinal study. Diabetes Res Clin Pract 2005, 68:81-83.
9. American Diabetes Association American Diabetes Association: Standards of medical care in diabetes 2011. Diabetes Care 2011, 34(Suppl 1):S11-S61.